United Therapeutics CEO exercises, sells 9,500 shares
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28.
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28. The trades were executed under a pre-arranged 10b5-1 trading plan adopted November 7, 2025 that covers up to 1,734,410 options expiring March 15, 2027. Following the exercise, a family trust holds 255,910 options, and Rothblatt reports 40,513 shares directly and 166 shares indirectly via her spouse, along with additional family-trust holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.72M approx. pre-tax spread)
Exercise and Sale
17 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.00M)
Approx. gross sale proceeds
$5.00M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.72M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F16 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 1,367 | $523.1544 | $715K |
| Sale | Common Stock F1, F4, F2 | 1,074 | $524.0387 | $563K |
| Sale | Common Stock F1, F5, F2 | 876 | $525.0206 | $460K |
| Sale | Common Stock F1, F6, F2 | 1,473 | $526.3372 | $775K |
| Sale | Common Stock F1, F7, F2 | 1,369 | $527.1568 | $722K |
| Sale | Common Stock F1, F8, F2 | 1,149 | $528.2024 | $607K |
| Sale | Common Stock F1, F9, F2 | 625 | $529.4118 | $331K |
| Sale | Common Stock F1, F10, F2 | 1,124 | $530.2918 | $596K |
| Sale | Common Stock F1, F11, F2 | 403 | $530.9703 | $214K |
| Sale | Common Stock F1, F12, F2 | 40 | $532.4895 | $21K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F13 | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
| holding | Common Stock F15 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 255,910 contracts (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (16)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $522.59 to $523.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $523.65 to $524.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $524.73 to $525.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $525.73 to $526.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $526.74 to $527.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $527.78 to $528.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $528.86 to $529.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F10. This transaction was executed in multiple trades at prices ranging from $529.88 to $530.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $530.88 to $531.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $532.44 to $532.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F15. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F16. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Key Figures
Options exercised: 9,500 shares
Shares sold: 9,500 shares
Representative sale price: $523.1544 per share
+4 more
7 metrics
Options exercised
9,500 shares
Stock options exercised on 2026-07-28 at $135.4200 per share by a family trust
Shares sold
9,500 shares
Total common shares sold across 10 open-market transactions on 2026-07-28
Representative sale price
$523.1544 per share
Weighted-average price for a 1,367-share sale of common stock on 2026-07-28
Remaining options in trust
255,910 options
Stock options held indirectly by a family trust following the reported exercise
Options under trading plan
1,734,410 options
Maximum stock options covered by the 10b5-1 trading plan adopted November 7, 2025
Direct common shares held
40,513 shares
Direct United Therapeutics common stock ownership reported as of 2026-07-28
Indirect shares via spouse
166 shares
Common stock held indirectly through spouse as of 2026-07-28
Key Terms
10b5-1 trading plan, weighted average price, family trusts, stock options
4 terms
10b5-1 trading plan regulatory
"pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
stock options financial
"exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did United Therapeutics (UTHR) CEO Martine Rothblatt report?
Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28 under a pre-arranged 10b5-1 trading plan.
What are the key terms of Martine Rothblatt’s 10b5-1 trading plan for UTHR?
The pre-arranged 10b5-1 trading plan was adopted on November 7, 2025. It will continue until the earlier of the exercise of 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026, guiding option exercises and related share sales.
How many United Therapeutics (UTHR) stock options are reported after these transactions?
After the reported exercise, a family trust associated with Rothblatt holds 255,910 stock options. Separately, the 10b5-1 trading plan contemplates the potential exercise of up to 1,734,410 options that all carry an expiration date of March 15, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
